• Earlier in January 2026, Ascendis Pharma A/S reported positive Week 52 topline Phase 2 COACH trial results for its once-weekly TransCon CNP and TransCon hGH combination in children with achondroplasia, alongside amending its Articles of Association to allow for new warrant grants.
• The COACH data highlighted durable growth, improved body proportionality, and a safety profile consistent with monotherapies, reinforcing TransCon CNP’s potential backbone role in treating achondroplasia as regulators review it under Priority Review in the US and Europe.
• With encouraging COACH trial outcomes and the Priority Review for TransCon CNP now in focus, we’ll explore how this shapes Ascendis Pharma’s investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

What Is Ascendis Pharma's Investment Narrative?

For Ascendis to make sense as a holding, you need to believe its TransCon platform can convert strong clinical data into durable, high-value franchises while the company manages ongoing losses and balance sheet pressure. The latest COACH Week 52 results fit neatly into that thesis: they strengthen the case for TransCon CNP as a foundation therapy in achondroplasia just as regulators work through its Priority Review in the US and Europe, sharpening what was already the key near term catalyst. At the same time, the additional warrant capacity underscores that equity-linked compensation and potential dilution remain part of the story for a business still investing heavily ahead of expected profitability. With the share price already up strongly over the past year, the question is how much of this regulatory and clinical momentum is now reflected in expectations.

However, one risk investors should be aware of is Ascendis’s negative shareholder equity position. Despite retreating, Ascendis Pharma's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span about US$222 to a very large US$848, showing how widely views differ on Ascendis’s potential. Set that against the heightened focus on TransCon CNP’s upcoming regulatory decisions and you can see why opinions on future performance vary so much.

Explore 4 other fair value estimates on Ascendis Pharma - why the stock might be worth over 3x more than the current price!

Build Your Own Ascendis Pharma Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ascendis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascendis Pharma's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Outshine the giants: these 23 early-stage AI stocks could fund your retirement.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.